Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback